Delving into the Latest Updates on Ubidecarenone with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Co-Enzyme Q10, Coenxyme Q10, Coenzyme Q-10

+ [26]

Target

HMOX1 x NOS2

Mechanism

HMOX1 modulators(Heme oxygenase 1 modulators), NOS2 stimulants(Nitric oxide synthase, inducible stimulants), Immunomodulators

Therapeutic Areas

Cardiovascular DiseasesNeoplasmsNervous System Diseases+ [5]

Active Indication

Heart FailureGlioblastoma MultiformeCoenzyme Q10 Deficiency+ [4]

Inactive Indication

Advanced Pancreatic AdenocarcinomaEpidermolysis BullosaNeoplasm Metastasis+ [2]

Originator Organization

Eisai Co., Ltd.

Active Organization

BPGbio Inc

Nobelpharma Co., Ltd.

University of Sao Paulo

+ [1]

Inactive Organization

Berg LLC

Drug Highest PhaseApproved

First Approval Date

JP (27 Jul 1976),

Heart Failure

RegulationOrphan Drug (US), Rare Pediatric Disease (US)

Login to view timeline

Structure

Molecular FormulaC59H90O4

InChIKeyACTIUHUUMQJHFO-UPTCCGCDSA-N

CAS Registry303-98-0

Heat stress, as an environmental stressor, can lead to temperature dysregulation and neuroinflammation, causing depression and anxiety by disrupting brain physiology and functional connectivity. This study looked at how co-enzyme Q10 (Q10) and vitamin E (Vit E), alone and together, affected heat stress-caused anxiety and depression symptoms and inflammation in male mice. Five groups were utilized in the study: control, heat stress (NS), Q10, Vit E, and the combination group (Q10+Vit E). The mice were subjected for 15 min/day to a temperature of 43°C for 14 consecutive days, followed by daily treatments for two weeks with either normal saline, Q10 (500 mg/kg), Vit E (250 mg/kg), or their combination. The forced swimming test (FST) and tail suspension test (TST) were employed to evaluate despair behavior, whereas the elevated plus maze (EPM) and open field test (OFT) were used to assess anxious behaviors. Subsequently, the animals were sacrificed, and serum corticosterone levels, protein expression of inflammasome-related proteins, and hsp70 gene expression were evaluated in the prefrontal cortex (PFC). The study revealed that treatment with Vit E and Q10, alone or together, provided anxiolytic and antidepressant effects in the heat-stress-subjected animals. Also, giving Vit E and Q10 alone or together greatly lowered serum corticosterone levels. In the PFC, they also lowered the levels of hsp70 mRNA and NF-κB, caspase 1, NLRP3, and IL-1β proteins. It is speculated that treatment with Q10 and Vit E can attenuate heat stress-associated anxious and depressive responses by inhibiting the inflammatory pathways and modulating the hypothalamus-pituitary-adrenal axis.

31 Dec 2024·Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Statement of Retraction: The effects of coenzyme Q10 supplementation on gene expression related to insulin, lipid and inflammation in patients with polycystic ovary syndrome

31 Dec 2024·ANNALS OF MEDICINE

Clinical evidence of coenzyme Q10 pretreatment for women with diminished ovarian reserve undergoing IVF/ICSI: a systematic review and meta-analysis

Review

Author: Jin Yie, Stella Lim ; Lin, Guangyao ; Xu, Lianwei ; Li, Xuanling

BACKGROUND:

To quantitatively evaluate the effect of coenzyme Q10 (CoQ10) pretreatment on outcomes of IVF or ICSI in women with diminished ovarian reserve (DOR) based on the existing randomized controlled trials (RCTs).

METHODS:

Nine databases were comprehensively searched from database inception to November 01, 2023, to identify eligible RCTs. Reproductive outcomes of interest consisted of three primary outcomes and six secondary outcomes. The sensitivity analysis was adopted to verify the robustness of pooled results.

RESULTS:

There were six RCTs in total, which collectively involved 1529 participants with DOR receiving infertility treatment with IVF/ICSI. The review of available evidence suggested that CoQ10 pretreatment was significantly correlated with elevated clinical pregnancy rate (OR = 1.84, 95%CI [1.33, 2.53], p = 0.0002), number of optimal embryos (OR = 0.59, 95%CI [0.21, 0.96], p = 0.002), number of oocytes retrieved (MD = 1.30, 95%CI [1.21, 1.40], p < 0.00001), and E₂ levels on the day of hCG (SMD = 0.37, 95%CI [0.07, 0.66], p = 0.01), along with a reduction in cycle cancellation rate (OR = 0.60, 95%CI [0.44, 0.83], p = 0.002), miscarriage rate (OR = 0.38, 95%CI [0.15, 0.98], p = 0.05), total days of Gn applied (MD = -0.89, 95%CI [-1.37, -0.41], p = 0.0003), and total dose of Gn used (MD = -330.44, 95%CI [-373.93, -286.96], p < 0.00001). The sensitivity analysis indicated that our pooled results were robust.

CONCLUSIONS:

These findings suggested that CoQ10 pretreatment is an effective intervention in improving IVF/ICSI outcomes for women with DOR. Still, this meta-analysis included relatively limited sample sizes with poor descriptions of their methodologies. Rigorously conducted trials are needed in the future.

42

News (Medical) associated with Ubidecarenone

28 Oct 2024

·www.prnewswire.com

Cocrystal Health Industry Announces Launch of Best in Class Bioabsorption and Stability Cocrystallized Lutein and Curcumin Technologies

Patented and clinically verified nutraceutical actives outperform current branded offerings and offer a powerful solution for supplement product potency concerns. LAS VEGAS, Oct. 28, 2024 /PRNewswire/ -- At the Supplyside West tradeshow this week representatives from Cocrystal Health Industry are announcing the launch of the Cocrystal Lutein and Curcumin powder actives. Backed by 60 global patents and near 100 published papers, the company leverages their proprietary and clean cocrystallization platform to produce actives with dramatically improved bioabsorption, stability and functionality relative to existing offerings. These launches build on their existing cocrystallized ingredient portfolio which includes Ubiquinol CoQ10, Hydroxytyrosol and Alpha Tocopherol Vitamin E. Continue Reading Cocrystal Curcumin Powder Cocrystal Lutein Powder Lutein is well demonstrated in clinical research to support eye health, though traditional lutein ingredients have poor bioabsorption, solubility, and stability, as the ingredient is easily oxidized. Powered by Cocrystal Health Industry's clean, vegan and non-GMO cocrystallization process, Cocrystal Lutein now provides a powerful solution to address these concerns. In 3rd party testing, Cocrystal Lutein demonstrated over 6 times greater bioabsorption and 3 times better solubility compared to current marketed lutein. In a head-to-head capsule stability study, the cocrystal advantage is even more dramatic. Cocrystal Lutein maintained over 99% of potency in capsules after 30 days, while current marketed lutein maintained less than 2% of its original potency. In addition to performance advantages, the cocrystal technology offers a significant cost savings relative to well known branded lutein. While well researched to support a range of benefits including joint and cognitive health, marketed curcumin extracts are similarly limited by very poor bioavailability. Patented Cocrystal Curcumin featuring L-Carnitine as a ligand has been shown in studies to offer over 10X greater bioabsorption in comparison to current marketed curcumin. And while there are several enhanced bioavailability curcumin materials available, in a head-to-head study Cocrystal Curcumin showed significantly better bioabsorption even relative to an existing enhanced offer. Alex Mei, PhD, Cocrystal Health Industry's Founder & CEO commented, "We are thrilled to expand our portfolio and introduce powerful new solutions in our Cocrystal Lutein & Curcumin technologies. Our proprietary platform solves for multiple nutrition brand concerns – providing meaningful differentiation and unparalleled benefit performance to their consumers, while ensuring sustained potency against label claim. As the global leader in cocrystallized active ingredients, we're proud to offer these transformative solutions." To learn more manufacturers and formulators can reach out to [email protected]. About Cocrystal Health Industry: Backed by 60 global patents and near 100 published papers, Cocrystal Health Industry introduces cocrystal powder technologies as unprecedented solutions for poor stability and low bioavailability ingredients. With demonstrated best in class bioavailability and superior in-formula stability, our actives also feature pure nature integrity, improved solubility, dissolution, melting point and flowability versus existing offerings. Beyond their superior performance, Cocrystal actives typically offer a cost advantage relative to other branded ingredients. The company's growing portfolio includes Cocrystal Ubiquinol, Hydroxytyrosol, Alpha Tocopherol, Rutin and now Lutein and Curcumin. For more information visit . Media Contact: Jeff Avila 305-632-1733 [email protected] SOURCE Cocrystal Health Industry WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

11 Oct 2024

·endpts.com

Sanofi lands on private equity firm CD&R as potential buyer of consumer health unit

Sanofi has chosen US private equity firm Clayton, Dubilier & Rice to advance acquisition talks for its consumer health unit, the pharma confirmed Friday. The company says it entered into negotiations with CD&R to sell a 50% controlling stake in its consumer health business, Opella. Reports say the firm’s offer values that 11,000-person business at €15.5 billion (roughly $17 billion). Sanofi is ultimately looking to offload its remaining share in the company in the next few years, according to the Financial Times . Consumer health divestments have been all the rage for pharmaceutical companies in the last couple of years. Johnson & Johnson spun out its unit into Kenvue in August 2023 , which currently has a market cap north of $40 billion. Earlier this month, Pfizer sold off a $3.3 billion stake in Haleon, a consumer venture partnered with GSK. Opella is the third-largest player in the over-the-counter and vitamin, mineral and supplements market, according to Sanofi. The portfolio includes over 100 brands, including household names like Icy Hot and the allergy medicine Allegra. Sanofi reported that the Opella business rose nearly 10% in the second quarter , thanks largely to the acquisition of Qunol. The supplements and vitamins brand includes the antioxidant CoQ10 and other turmeric-based products. Opella represented about 13.3% of Sanofi’s total business through the first half of the year, the remainder coming from the biopharma segment. CFO François-Xavier Roger said on the company’s second-quarter earnings call in July that the company was mulling three options: a spinout, an IPO or a sale. He conveyed that as of that point, all options were still on the table. “The game is still totally open as we speak with one objective, which is value creation for shareholders,” he said. The two main considerations then were valuation and the “execution risk,” he added. Sanofi said Friday that more updates on the sale will be provided in the future, “when a decision is made.”

AcquisitionIPO

01 Oct 2024

·www.pharmaceutical-technology.com

BPGbio’s mitochondrial disorder drug gets paediatric disease status

Primary CoQ10 deficiency is a rare mitochondrial disorder that impacts fewer than one in 100,000 individuals. Credit: StudioMolekuul via Shutterstock. BPGbio has received a Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for BPM31510IV to treat primary coenzyme Q10 deficiency, an ultra-rare mitochondrial disorder. Primary CoQ10 deficiency affects fewer than one in 100,000 people. It hampers the body’s ability to produce CoQ10, a molecule crucial for cellular energy production and biomembrane stabilisation. The deficiency can lead to severe developmental delays, weakness of muscle, seizures, and potentially fatal organ damage, with symptoms often appearing in early childhood. Oral CoQ10 supplements failed to reach therapeutic levels in severely affected organs. BPGbio’s BPM31510IV has shown potential in addressing this gap, leveraging the company’s NAi Interrogative Biology platform, which combines patient biology with AI-driven analysis. See Also: Potential for peptides to replace antibodies in radiopharma, says WuXi AppTec exec BPGbio’s mitochondrial disorder drug gets paediatric disease status It is not only a lead candidate for solid tumours such as glioblastoma multiforme and pancreatic cancer but also shows promise for various rare diseases. BPGbio president and CEO Niven Narain said: “BPM31510 has been developed in topical, IV and oral formulations and is a prime example of the power of our biology-first approach to drug discovery and development, illustrating the powerful predictive capabilities of our NAi Interrogative Biology platform, and the benefit of validating AI-derived predictions through wet lab experiments and in vivo modelling. “By using hypothesis-free causal AI to analyse vast amounts of biological data, we were able to uncover and validate new potential applications BPM31510, including its potential to address mitochondrial diseases like primary CoQ10 deficiency.” BPGbio’s investigational treatment has also received orphan drug designation for glioblastoma multiforme, pancreatic cancer, and epidermolysis bullosa, in addition to the rare pediatric disease designation for primary CoQ10 deficiency.

Orphan Drug

100 Deals associated with Ubidecarenone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01065	Ubidecarenone	C01EB09	DB09270

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	JP	Eisai Co., Ltd.	27 Jul 1976

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioblastoma Multiforme	Phase 2	US	BPGbio Inc	22 Aug 2022
Advanced Pancreatic Adenocarcinoma	Phase 2	US	Berg LLC	06 Jul 2016
Advanced Pancreatic Adenocarcinoma	Phase 2	GB	Berg LLC	06 Jul 2016
Squamous Cell Carcinoma	Phase 2	-	Berg LLC	01 Mar 2008
Superficial basal cell carcinoma	Phase 2	US	Berg LLC	01 Mar 2008
Coenzyme Q10 Deficiency	Phase 2	US	BPGbio Inc	-
Multiple System Atrophy	Phase 2	JP	Nobelpharma Co., Ltd.	-
Pancreatic Cancer	Phase 2	US	BPGbio Inc	-
Epidermolysis Bullosa	Phase 1	US	Berg LLC	10 Aug 2016
Neoplasm Metastasis	Phase 1	US	Berg LLC	01 Oct 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02650804 (Biospace) Manual	Phase 2	Pancreatic Cancer Second line \| Third line	19	BPM31510+gemcitabine	gidhuuhwgf(ksdjjezjtg) = mwnhqifzuv vbpdjtgwij (eexrxtxwwc )	Positive	18 Jan 2024
				Gemcitabine	gidhuuhwgf(ksdjjezjtg) = ygnqskctsh vbpdjtgwij (eexrxtxwwc )
EASD2023	Not Applicable	Metabolic dysfunction-associated steatotic liver disease	52	Coenzyme Q10 240mg	qwlahvykui(gnilitmkpn) = tcvsemoytb nfhnzozfcg (uyvayiygtv ) View more	Positive	05 Oct 2023
				coenzyme Q10	qwlahvykui(gnilitmkpn) = xoigqpvswx nfhnzozfcg (uyvayiygtv ) View more
Pubmed \| Eur J Obstet Gynecol Reprod Biol	Not Applicable	-	-	coenzyme Q10 (Frozen-thawed control (Ctrl))	dwcmzmqurk(jhngufnqov) = DNA fragmentation was significantly increased in the curcumin-added groups bsgioezfjp (hhemtfqqgu )	-	01 Aug 2023
				Frozen-thawed with curcumin supplementation of 0.25 mM (Cur)
ARVO2023	Not Applicable	-	-	coenzyme Q10	jjazfeubcs(wrinslmjsb) = fqpazujozz cosvpupoom (eoavadeyif ) View more	-	23 Apr 2023
				H2O2+CoQ10	jjazfeubcs(wrinslmjsb) = snclcpzocw cosvpupoom (eoavadeyif ) View more
NCT02865460 (CTgov)	Phase 3	Fatigue Syndrome, Chronic \| Persian Gulf Syndrome \| Coenzyme Q10 Deficiency	100	Ubiquinol (Ubiquinol)	hhshmzlslv(qkeisyythz) = kjatfabuys kdytmcmomj (qpgnkypzxp, wkqmjlcdfp - fgfzsgarcr) View more	-	15 Feb 2023
				Placebo (Placebo)	hhshmzlslv(qkeisyythz) = cdwyvxuzdg kdytmcmomj (qpgnkypzxp, gxdxrensru - qsubjlrbmw) View more
EUCTR2020-005961-16-DK \| NCT04960215 (Pubmed)	Phase 2	Post Acute COVID 19 Syndrome	121	Coenzyme Q10 500 mg/day	erlnjvtadu(bfbksciens): mean difference = 0.01 (95% CI, -0.02 to 0.04), P-Value = 0.45 View more	Negative	02 Nov 2022
				coenzyme Q10 (Placebo)
NCT03133793 (CTgov)	Phase 2	Heart Failure, Diastolic	216	Placebo powder (Placebo Only)	ohrevenble(tbepxiutnh) = ossmxhcyqk gbtxowmgcx (cqwqphkdqn, csrvpvoehk - qdnetuiekr) View more	-	03 Mar 2022
				Placebo powder+CoQ10 (CoQ10 Only)	ohrevenble(tbepxiutnh) = xgnzjtepya gbtxowmgcx (cqwqphkdqn, mwigthfqxi - rkuioawjms) View more
ISN WCN2022	Not Applicable	Coenzyme Q10 Deficiency \| Nephrotic Syndrome	-	CoQ10 (COQ2)	zzaewscxnu(voyzjnucxf) = ojiebbyinv patwwqcull (zllanqqnsm ) View more	-	01 Feb 2022
				CoQ10 (COQ6)	zzaewscxnu(voyzjnucxf) = quktckuaxv patwwqcull (zllanqqnsm ) View more
NCT02934555 (CTgov)	Phase 2	Post-Cardiac Arrest Syndrome \| Heart Arrest	48	Ensure+Ubiquinol	ufsdfliwki(eslfbxzwhj) = hrguaabjag ltumtkexoo (qltphypjyt, xpnntiiwdd - wogfmqijyd) View more	-	15 Feb 2021
ESMO2020	Phase 2	Advanced Pancreatic Ductal Adenocarcinoma	35	BPM 31510-IV + gemcitabine	gkufcgrxll(siexltbhpp) = wjwlijutjt lgpvuabavy (drqruzlgrj ) View more	-	17 Sep 2020